Literature DB >> 31274040

Clinical applicability of proposed algorithm for identifying individuals at risk for hereditary hematologic malignancies.

Maggie Clifford1,2, Sarah Bannon3, Erica M Bednar3, Jennifer Czerwinski4, Jessica Davis5, Leslie Dunnington6, S Shahrukh Hashmi7, Courtney D DiNardo8.   

Abstract

Multiple genes have been identified to cause hereditary predispositions to hematologic malignancies, and characterized by an increased risk to develop myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and/or aplastic anemia (AA). Referral algorithms for patients who may be at higher risk have been proposed, with limited data regarding applicability. Our study aimed to evaluate referral criteria on a population of MDS/AML/AA patients. Demographic information and medical history were obtained from 608 patients referred over a 9-month period. Median age at diagnosis was 67 years (56-73), 387 (64%) were male, and the majority of individuals (54.9%) had AML. Overall, 406 individuals (66.8%) had insufficient documentation to determine whether certain criteria were met. Two hundred and two (33.2%) individuals met at least one criteria for genetic counseling referral; however, only nine (4.5%) were referred. Increased documentation of personal and family history is necessary to better assess and validate the applicability of these criteria.

Entities:  

Keywords:  Hereditary hematologic malignancies; cancer genetics risk assessment; clinical detection algorithm; identifying at risk individuals; leukemia

Year:  2019        PMID: 31274040      PMCID: PMC6858528          DOI: 10.1080/10428194.2019.1630618

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  19 in total

1.  Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome.

Authors:  Amy P Hsu; Elizabeth P Sampaio; Javed Khan; Katherine R Calvo; Jacob E Lemieux; Smita Y Patel; David M Frucht; Donald C Vinh; Roger D Auth; Alexandra F Freeman; Kenneth N Olivier; Gulbu Uzel; Christa S Zerbe; Christine Spalding; Stefania Pittaluga; Mark Raffeld; Douglas B Kuhns; Li Ding; Michelle L Paulson; Beatriz E Marciano; Juan C Gea-Banacloche; Jordan S Orange; Jennifer Cuellar-Rodriguez; Dennis D Hickstein; Steven M Holland
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

2.  Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Authors:  Erdogan Taskesen; Lars Bullinger; Andrea Corbacioglu; Mathijs A Sanders; Claudia A J Erpelinck; Bas J Wouters; Sonja C van der Poel-van de Luytgaarde; Frederik Damm; Jürgen Krauter; Arnold Ganser; Richard F Schlenk; Bob Löwenberg; Ruud Delwel; Hartmut Döhner; Peter J M Valk; Konstanze Döhner
Journal:  Blood       Date:  2010-12-21       Impact factor: 22.113

Review 3.  Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes.

Authors:  Jane E Churpek; Rachelle Lorenz; Siya Nedumgottil; Kenan Onel; Olufunmilayo I Olopade; April Sorrell; Carolyn J Owen; Alison A Bertuch; Lucy A Godley
Journal:  Leuk Lymphoma       Date:  2012-07-09

4.  Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome).

Authors:  Pia Ostergaard; Michael A Simpson; Fiona C Connell; Colin G Steward; Glen Brice; Wesley J Woollard; Dimitra Dafou; Tatjana Kilo; Sarah Smithson; Peter Lunt; Victoria A Murday; Shirley Hodgson; Russell Keenan; Daniela T Pilz; Ines Martinez-Corral; Taija Makinen; Peter S Mortimer; Steve Jeffery; Richard C Trembath; Sahar Mansour
Journal:  Nat Genet       Date:  2011-09-04       Impact factor: 38.330

Review 5.  Pathophysiology and management of inherited bone marrow failure syndromes.

Authors:  Akiko Shimamura; Blanche P Alter
Journal:  Blood Rev       Date:  2010-04-24       Impact factor: 8.250

6.  Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA.

Authors:  Patrick F Fogarty; Hiroki Yamaguchi; Adrian Wiestner; Gabriela M Baerlocher; Elaine Sloand; Weihua S Zeng; Elizabeth J Read; Peter M Lansdorp; Neal S Young
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

Review 7.  Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia.

Authors:  Peter Ganly; Logan C Walker; Christine M Morris
Journal:  Leuk Lymphoma       Date:  2004-01

8.  Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy.

Authors:  Carolyn J Owen; Cynthia L Toze; Anna Koochin; Donna L Forrest; Clayton A Smith; Jane M Stevens; Shannon C Jackson; Man-Chiu Poon; Gary D Sinclair; Brian Leber; Peter R E Johnson; Anthony Macheta; John A L Yin; Michael J Barnett; T Andrew Lister; Jude Fitzgibbon
Journal:  Blood       Date:  2008-08-21       Impact factor: 22.113

9.  Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC).

Authors:  Courtney D DiNardo; Sarah A Bannon; Mark Routbort; Anna Franklin; Maureen Mork; Mary Armanios; Emily M Mace; Jordan S Orange; Meselle Jeff-Eke; Jane E Churpek; Koichi Takahashi; Jeffrey L Jorgensen; Guillermo Garcia-Manero; Steve Kornblau; Alison Bertuch; Hannah Cheung; Kapil Bhalla; Andrew Futreal; Lucy A Godley; Keyur P Patel
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-04-27

10.  Germline Mutations in Predisposition Genes in Pediatric Cancer.

Authors:  Jinghui Zhang; Michael F Walsh; Gang Wu; Kim E Nichols; Michael N Edmonson; Tanja A Gruber; John Easton; Dale Hedges; Xiaotu Ma; Xin Zhou; Donald A Yergeau; Mark R Wilkinson; Bhavin Vadodaria; Xiang Chen; Rose B McGee; Stacy Hines-Dowell; Regina Nuccio; Emily Quinn; Sheila A Shurtleff; Michael Rusch; Aman Patel; Jared B Becksfort; Shuoguo Wang; Meaghann S Weaver; Li Ding; Elaine R Mardis; Richard K Wilson; Amar Gajjar; David W Ellison; Alberto S Pappo; Ching-Hon Pui; James R Downing
Journal:  N Engl J Med       Date:  2015-11-18       Impact factor: 91.245

View more
  1 in total

Review 1.  Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.

Authors:  Kristen E Schratz; Amy E DeZern
Journal:  Hematol Oncol Clin North Am       Date:  2020-01-06       Impact factor: 3.722

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.